• A Biomedical Scientist with MCS: Anita Wasik, Ph.D.

  • Nov 9 2024
  • Length: 32 mins
  • Podcast

A Biomedical Scientist with MCS: Anita Wasik, Ph.D.

  • Summary

  • Episode 59 of The Chemical Sensitivity Podcast is available now!

    It's called “A Biomedical Scientist with MCS.”

    It features a conversation with Dr. Anita Wasik, a medical herbalist with a PhD in Medicine based in Finland. She has so much knowledge about MCS and also has the condition.

    You’ll hear Dr. Wasik explore:

    • Her own experiences with MCS and related conditions.
    • How exposure to toxic mold can lead to and contribute to MCS.
    • How the chemical industry influences research and medicine to dismiss MCS.
    • Why she thinks more and more people will develop MCS going forward.
    • How herbal medicine can assist people with the illness.

    Thank you for listening. Please subscribe where you get your podcasts.

    #MCSAwareness #MCS #MultipleChemicalSensitivity #TILT

    More info about Dr. Wasik:
    https://www.anitawasik.com/





    Support the show

    Thank you very much to the Marilyn Brachman Hoffman Foundation for its generous support of the podcast.

    If you like the podcast, please consider becoming a supporter!

    • Support the podcast.
    • Find the podcast on Patreon.
    • If you like, please buy me a coffee.

    Follow the podcast on YouTube! Read captions in any language.

    Please follow the podcast on social media:
    Facebook
    Instagram
    X
    BlueSky
    TikTok

    Sponsorship Opportunites

    Are you an organization or company interested in helping to create greater awareness about Multiple Chemical Sensitivity and Chemical Intolerance and/or looking for sponsorship opportunities? Please email us at info@chemicalsensitivitypodcast.org




    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about A Biomedical Scientist with MCS: Anita Wasik, Ph.D.

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.